Arnauld Villers

Arnauld Villers

Auto-generated profile, based on publicly available information

Arnauld Villers

Department of Urology, Lille University Hospital, 59000 Lille, France

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
FSFritz H. Schröder
Fritz H. Schröder
JHJonas Hugosson
Jonas Hugosson
Monique RoobolMonique Roobol
Monique Roobol
TTTeuvo L.J. Tammela
Teuvo L.J. Tammela
SCStefano Ciatto
Stefano Ciatto
AAAnssi Auvinen
Anssi Auvinen
The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific–antigen (PSA) testing on death rates from prostate cancer. We identified 182,000 men between the ages of 50 and 74 years through registries in seven European countries for inclusion in our study. The men were randomly assigned to a group that was offered PSA screening at an average of once every 4 years or to a control group that did not receive such screening. The predefined core age group for this study included 162,243 men between the ages of 55 and 69 years. The primary outcome was the rate of death from prostate cancer. Mortality follow-up was identical for the two study groups and ended on December 31, 2006. In the screening group, 82% of men accepted at least one offer of screening. During a median follow-up of 9 years, the cumulative incidence of prostate cancer was 8.2% in the screening group and 4.8% in the control group. The rate ratio for death from prostate cancer in the screening group, as compared with the control group, was 0.80 (95% confidence interval [CI], 0.65 to 0.98; adjusted P=0.04). The absolute risk difference was 0.71 death per 1000 men. This means that 1410 men would need to be screened and 48 additional cases of prostate cancer would need to be treated to prevent one death from prostate cancer. The analysis of men who were actually screened during the first round (excluding subjects with noncompliance) provided a rate ratio for death from prostate cancer of 0.73 (95% CI, 0.56 to 0.90). PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis. (Current Controlled Trials number, ISRCTN49127736.)

18 March 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
VKVeeru Kasivisvanathan
Veeru Kasivisvanathan
ARAntti Rannikko
Antti Rannikko
MBMarcelo Borghi
Marcelo Borghi
VPValeria Panebianco
Valeria Panebianco
LMLance A. Mynderse
Lance A. Mynderse
CMCaroline M. Moore
Caroline M. Moore
Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography–guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited.

1 December 2014 in The Lancet
Verified
Journal Article
Closed access
FSFritz H Schröder
Fritz H Schröder
JHJonas Hugosson
Jonas Hugosson
Monique RoobolMonique Roobol
Monique Roobol
TTTeuvo L J Tammela
Teuvo L J Tammela
MZMarco Zappa
Marco Zappa
AAAnssi Auvinen
Anssi Auvinen

15 March 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
FSFritz H. Schröder
Fritz H. Schröder
JHJonas Hugosson
Jonas Hugosson
MRMonique J. Roobol
Monique J. Roobol
TTTeuvo L.J. Tammela
Teuvo L.J. Tammela
SCStefano Ciatto
Stefano Ciatto
AAAnssi Auvinen
Anssi Auvinen
Several trials evaluating the effect of prostate-specific antigen (PSA) testing on prostate-cancer mortality have shown conflicting results. We updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with 2 additional years of follow-up. The study involved 182,160 men between the ages of 50 and 74 years at entry, with a predefined core age group of 162,388 men 55 to 69 years of age. The trial was conducted in eight European countries. Men who were randomly assigned to the screening group were offered PSA-based screening, whereas those in the control group were not offered such screening. The primary outcome was mortality from prostate cancer. After a median follow-up of 11 years in the core age group, the relative reduction in the risk of death from prostate cancer in the screening group was 21% (rate ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P=0.001), and 29% after adjustment for noncompliance. The absolute reduction in mortality in the screening group was 0.10 deaths per 1000 person-years or 1.07 deaths per 1000 men who underwent randomization. The rate ratio for death from prostate cancer during follow-up years 10 and 11 was 0.62 (95% CI, 0.45 to 0.85; P=0.003). To prevent one death from prostate cancer at 11 years of follow-up, 1055 men would need to be invited for screening and 37 cancers would need to be detected. There was no significant between-group difference in all-cause mortality. Analyses after 2 additional years of follow-up consolidated our previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality. (Current Controlled Trials number, ISRCTN49127736.)

1 December 2015 in European Urology
Verified
Journal Article
Closed access
JFJurgen Fütterer
Jurgen Fütterer
ABAlberto Briganti
Alberto Briganti
PVPieter De Visschere
Pieter De Visschere
MEMark Emberton
Mark Emberton
GGGianluca Giannarini
Gianluca Giannarini
AVArnauld Villers
Arnauld Villers

1 April 2011 in European Urology
Verified
Journal Article
Closed access
LDLouise Dickinson
Louise Dickinson
HAHashim U. Ahmed
Hashim U. Ahmed
CAClare Allen
Clare Allen
JBJelle O. Barentsz
Jelle O. Barentsz
BCBrendan Carey
Brendan Carey
MEMark Emberton
Mark Emberton